Biotechnology

AIM VACCINE

AIM VACCINE released FY2025 9 Months Earnings on March 30 (BJT), actual revenue HKD 913.08 M, actual EPS HKD -0.3616

AIM VACCINE released FY2025 Q3 earnings on March 30 (BJT), actual revenue HKD 355.83 M, actual EPS HKD -0.2425

AIM VACCINE released FY2025 annual earnings on March 30 During-Market (BJT), actual revenue HKD 1.274 B (forecast HKD 1.466 B), actual EPS HKD -0.6011

AIM VACCINE released FY2025 Q4 earnings on March 30 During-Market (BJT), actual revenue HKD 361.98 M, actual EPS HKD -0.2467

AIM VACCINE to Release FY2025 Annual Earnings on March 30 During-Market (BJT), Forecast Revenue HKD 1.441 B

Eimicai's 20-valent Pneumococcal Conjugate Vaccine Receives Clinical Trial Approval

Emei Vaccine Co., Ltd. Completes Phase III Clinical Trials for Enhanced Rabies Vaccine

AIM VACCINE released FY2025 Q1 earnings on August 27 (BJT), actual revenue HKD 275.59 M, actual EPS HKD -0.0589

AIM VACCINE released FY2025 Semi-Annual Earnings on August 27 During-Market (BJT), actual revenue HKD 557.24 M, actual EPS HKD -0.1191

AIM VACCINE released FY2025 Q2 earnings on August 27 During-Market (BJT), actual revenue HKD 281.65 M, actual EPS HKD -0.0601

AIM VACCINE to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Emei Vaccine's mRNA Shingles Vaccine Approved in China and US

AIM Vaccine's ESG Rating Dropped to BB

Emcure's mRNA Shingles Vaccine Approved in China and US

EimicVac Approved for Iterative mRNA Shingles Vaccine Clinical Trials in China and US

Eve Vaccine Adjusts Board Members to Strengthen Corporate Governance

Ai Mei Vaccine's Serum-Free Iterative Rabies Vaccine Approved for Market Registration by the National Medical Products Administration

AIM VACCINE released FY2024 9 months earnings on March 28 (BJT), actual revenue 994.18 M HKD, actual EPS -0.1905 HKD

AIM VACCINE released FY2024 Q3 earnings on March 28 (BJT), with actual revenue of 414.48 M HKD and EPS of -0.0665 HKD

Aimei Vaccine Announces 2024 Performance, Revenue Approximately 1.285 Billion Yuan, Up 8.2% Year-on-Year

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02656

02706

06660

00580

02865

02617

02477

00259

00596

02940

160 HEALTH(02656) rose 44.26%, with a trading turnover 2.4 Billion HKD, and a year-to-date fell 57.9%. HAIZHI TECH GP(02706) rose 25.96%, with a trading turnover 363.0 Million HKD, and a year-to-date rose 129.5%. AIM VACCINE(06660) rose 21.83%, with a trading turnover 10.6 Million HKD, and a year-to-date fell 4.4%.

Top Gainers&Losers

160 HEALTH

HAIZHI TECH GP

SUN.KING TECH

DRINDA

TRANSTHERA-B

WELLCELL HOLD

YEEBO (INT'L H)

INSPUR DIGI ENT

Top 10 HK Stock Gainers (5.8)

02655

02517

06656

09887

01384

02595

03986

02788

GUOXIA TECH(02655) fell 24.04%, with a trading turnover 653.6 Million HKD, and a year-to-date rose 9.2%. GUOQUAN(02517) fell 11.17%, with a trading turnover 338.8 Million HKD, and a year-to-date fell 13.4%. SIGENERGY(06656) fell 9.02%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 85.1%.

GUOXIA TECH

GUOQUAN

SIGENERGY

LEADS BIOLABS-B

DEEPEXI TECH

GENFLEET-B

GIGADEVICE

CHUANGXIN IND

Top 10 HK Stock Losers (4.17)

159849

159316

520880

560600

512290

159859

516820

159102

AIM VACCINE announced its full-year results for the year ended December last year, with a revenue of 1.166 billion yuan (RMB), a year-on-year decrease of 9.3%. The loss widened to 675 million yuan, compared to a loss of 277 million yuan in the same period last year; the loss per share was 0.55 yuan. No final dividend will be distributed

AASTOCKS

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

"Performance" AIM VACCINE's losses widened to 675 million yuan last year

AIM Vaccine Swings to Deeper 2025 Loss on Impairments and Revenue Decline

Tip Ranks

AIM Vaccine Swings to Deeper 2025 Loss on Impairments and Revenue Decline

AIM Vaccine Plans Beijing A-Share Listing and New Domestic Share Issuance

AIM Vaccine Plans Beijing A-Share Listing and New Domestic Share Issuance

AIM VACCINE(06660.HK)

Top 10 HK Stock Gainers (5.8)

Top 10 HK Stock Losers (4.17)

"Performance" AIM VACCINE's losses widened to 675 million yuan last year

AIM Vaccine Swings to Deeper 2025 Loss on Impairments and Revenue Decline

AIM Vaccine Plans Beijing A-Share Listing and New Domestic Share Issuance